

19. Wu S, Kanda T, Imazeki F, et al. Hepatitis B virus e antigen downregulates cytokine production in human hepatoma cell lines. *Viral Immunol.* 2010; 23: 467-476.
20. Usuda S, Okamoto H, Iwanari H, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. *J Virol Methods.* 1999; 80: 97-112.
21. Gallego A, Sheldon J, Garcia-Samaniego J, et al. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. *J Viral Hepat.* 2008; 15: 392-398.
22. Fujiwara K, Yokosuka O, Ehata T, et al. The two different states of hepatitis B virus DNA in asymptomatic carriers: HBe-antigen-positive versus anti-HBe-positive asymptomatic carriers. *Dig Dis Sci.* 1998; 43: 368-376.
23. Mendes-Correa MC, Pinho JR, Gomes-Gouvea MS, et al. Predictors of HBeAg status and hepatitis B viremia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil. *BMC Infect Dis.* 2011; 11: 247.
24. Wong VW, Wong GL, Yiu KK, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. *J Hepatol.* 2011; 54: 236-242.
25. Sarin SK, Sandhu BS, Sharma BC, et al. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT. *J Viral Hepat.* 2004; 11: 552-558.
26. Fujisaki S, Yokomaku Y, Shiino T, et al. Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfecting with HIV-1 in Japan. *J Clin Microbiol.* 2011; 49: 1017-1024.
27. Lindh M, Uhnoo I, Blackberg J, et al. Treatment of chronic hepatitis B infection: An update of Swedish recommendations. *Scand J Infect Dis.* 2008; 40: 436-450.
28. Seta T, Yokosuka O, Imazeki F, et al. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. *J Med Virol.* 2000; 60: 8-16.
29. Kusumoto S, Tanaka Y, Ueda R, et al. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. *J Gastroenterol.* 2011; 46: 9-16.
30. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. *Hepatology.* 2006; 43: 209-220.

